Survival of biological therapeutics in psoriasis: retrospective analysis of 3-years data in a Turkish registry, PSORTAKSIS

Basit Öğe Kaydı
dc.contributor.authorOzyurt, Kemal
dc.contributor.authorZararsiz, Gokmen
dc.contributor.authorErta, Ragip
dc.contributor.authorCephe, Ahu
dc.contributor.authorKutlu, Omer
dc.contributor.authorElmas, Omer Faruk
dc.contributor.authorAkku, Muhammet Resat
dc.date.accessioned2025-01-21T16:34:38Z
dc.date.available2025-01-21T16:34:38Z
dc.date.issued2022
dc.departmentKırıkkale Üniversitesi
dc.description.abstractBackground/aim: PSORTAKSIS is a psoriasis registry, which is used for follow-up of patients in Kayseri City Education and Research Hospital, Dermatology Clinic since 2016 in Turkey. PSORTAKSIS includes demographic data, follow-up clinical findings, laboratory output, and treatment information of patients. Here, drug survivals of biologic therapeutics (BT) according to three-year data of PSORTAKSIS will be presented. Materials and methods: Drug survival of BT in PSORTAKSIS was analyzed from 2016 to March 2019. Results: 158 patients (111 of them BT-naive) with psoriasis under BT were enrolled in the current study. Drug survival analysis of patients with ongoing BT (158 treatment periods) revealed mean survival time as 15.49 months for ustekinumab, 15.37 months for adalimumab, 14.00 months for etanercept, 5 months for infliximab, and 4.59 months for secukinumab. The differences between drug survivals of BT were statistically significant (log-rank test, chi(2) = 79.915, p < 0.0001). Age of onset was found to be the only independent risk factor of drug survival according to regression analysis (p = 0.029). Conclusion: As a conclusion, drug survival of UST was significantly higher than that of TNF-alpha inhibitors and SEC in the treatment of psoriasis. This study revealed that among predictors, age at disease onset may influence drug survival.
dc.identifier.doi10.3906/sag-2104-339
dc.identifier.endpage66
dc.identifier.issn1300-0144
dc.identifier.issn1303-6165
dc.identifier.issue1
dc.identifier.pmid34365780
dc.identifier.scopus2-s2.0-85125325790
dc.identifier.scopusqualityQ1
dc.identifier.startpage58
dc.identifier.trdizinid516847
dc.identifier.urihttps://doi.org/10.3906/sag-2104-339
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay516847
dc.identifier.urihttps://hdl.handle.net/20.500.12587/23996
dc.identifier.volume52
dc.identifier.wosWOS:000761923700007
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherTubitak Scientific & Technological Research Council Turkey
dc.relation.ispartofTurkish Journal of Medical Sciences
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_20241229
dc.subjectPsoriasis; drug survival; anti-TNF; ustekinumab; secukinumab; psoriasis registry
dc.titleSurvival of biological therapeutics in psoriasis: retrospective analysis of 3-years data in a Turkish registry, PSORTAKSIS
dc.typeArticle

Dosyalar

Koleksiyon

WOS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu